In a report released today, Danielle Brill from Raymond James maintained a Buy rating on Argenx Se (ARGX). The company’s shares closed last Wednesday at $227.67.
According to TipRanks.com, Brill is a 5-star analyst with an average return of 20.2% and a 56.1% success rate. Brill covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Sarepta Therapeutics.
Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $256.02.
See today’s analyst top recommended stocks >>
The company has a one-year high of $272.74 and a one-year low of $103.75. Currently, Argenx Se has an average volume of 178.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
